S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
66,000% upside on tiny biotech? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
66,000% upside on tiny biotech? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
66,000% upside on tiny biotech? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
66,000% upside on tiny biotech? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
NYSE:RCUS

Arcus Biosciences (RCUS) Stock Forecast, Price & News

$17.95
-0.11 (-0.61%)
(As of 09/29/2023 ET)
Compare
Today's Range
$17.62
$18.48
50-Day Range
$17.62
$23.04
52-Week Range
$15.70
$36.13
Volume
877,773 shs
Average Volume
671,028 shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.00

Arcus Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
145.1% Upside
$44.00 Price Target
Short Interest
Healthy
13.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.22mentions of Arcus Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.36 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.33) to ($3.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

174th out of 972 stocks

Pharmaceutical Preparations Industry

62nd out of 449 stocks


RCUS stock logo

About Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Price History

RCUS Stock News Headlines

Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
Arcus Biosciences (NYSE: RCUS)
Truist Financial Remains a Buy on Arcus Biosciences (RCUS)
Arcus Biosciences (RCUS): A Modestly Undervalued Gem?
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
5 Analysts Have This to Say About Arcus Biosciences
Arcus Biosciences: A Modestly Undervalued Opportunity?
Arcus Biosciences (RCUS) Receives a Buy from Mizuho Securities
Arcus Biosciences, Inc Q2 Loss increases, but beats estimates
Preview: Arcus Biosciences's Earnings
See More Headlines
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Company Calendar

Last Earnings
8/07/2023
Today
10/01/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+145.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-267,000,000.00
Net Margins
-235.99%
Pretax Margin
-233.59%

Debt

Sales & Book Value

Annual Sales
$112 million
Book Value
$9.07 per share

Miscellaneous

Free Float
64,222,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.82
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Terry J. Rosen Ph.D. (Age 63)
    Co-Founder, Chairman & CEO
    Comp: $756.11k
  • Dr. Juan Carlos Jaen Ph.D. (Age 65)
    Co-Founder, Pres & Director
    Comp: $931.14k
  • Mr. Robert C. Goeltz IIMr. Robert C. Goeltz II (Age 50)
    Principal Financial Officer & CFO
    Comp: $745.29k
  • Ms. Jennifer A. Jarrett M.B.A. (Age 52)
    COO & Director
    Comp: $925.29k
  • Dr. Dimitry S.A. Nuyten M.D. (Age 47)
    Ph.D., Chief Medical Officer
    Comp: $700.34k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Alexander Azoy (Age 47)
    VP of Fin. & Principal Accounting Officer
  • Dr. Stephen Young Ph.D. (Age 54)
    Sr. VP of Technology & Quantitative Biology
  • Dr. Jonathan Yingling Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Katherine Bock
    VP of Investor Relations & Corp. Strategy













RCUS Stock - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCUS shares.
View RCUS analyst ratings
or view top-rated stocks.

What is Arcus Biosciences' stock price forecast for 2023?

9 analysts have issued twelve-month price targets for Arcus Biosciences' stock. Their RCUS share price forecasts range from $23.00 to $70.00. On average, they anticipate the company's share price to reach $44.00 in the next twelve months. This suggests a possible upside of 145.1% from the stock's current price.
View analysts price targets for RCUS
or view top-rated stocks among Wall Street analysts.

How have RCUS shares performed in 2023?

Arcus Biosciences' stock was trading at $20.68 on January 1st, 2023. Since then, RCUS shares have decreased by 13.2% and is now trading at $17.95.
View the best growth stocks for 2023 here
.

When is Arcus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our RCUS earnings forecast
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) announced its quarterly earnings results on Monday, August, 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $0.06. The firm had revenue of $29 million for the quarter, compared to analysts' expectations of $31.81 million. Arcus Biosciences had a negative net margin of 235.99% and a negative trailing twelve-month return on equity of 45.51%. Arcus Biosciences's revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.93) earnings per share.

What ETFs hold Arcus Biosciences' stock?
What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?
When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $17.95.

How much money does Arcus Biosciences make?

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.34 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.

How many employees does Arcus Biosciences have?

The company employs 500 workers across the globe.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.

This page (NYSE:RCUS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -